Cited by 64Cancer, Hypoxia, and MetabolismCancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Gain of HIF-1α under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes

Open access
Lee, Young-Ho, Bae, Hyun Cheol, Noh, Kyung Hee, Song, Kwon-Ho, Ye, Sang-kyu, Mao, Chih-Ping, Lee, Kyung-Mi, Wu, T.-C. +1 more·2015·Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: Adaptation to host immune surveillance is now recognized as a hallmark of cancer onset and progression, and represents an early, indispensable event in cancer evolution. This process of evolution is first instigated by an immune selection pressure imposed by natural host surveillance mechanisms and may then be propagated by vaccination or other types of immunotherapy. Experimental Design: We developed a system to simulate cancer evolution in a live host and to dissect the mechanisms responsible for adaptation to immune selection. Here, we show that the oxygen-sensitive α subunit of hypoxia-inducible factor 1 (HIF-1α) plays a central role in cancer immune adaptation under conditions of normal oxygen tension. Results: We found that tumor cells gain HIF-1α in the course of immune selection under normoxia and that HIF-1α renders tumor cells resistant to lysis by tumor-specific cytotoxic T lymphocytes (CTL) in culture and in mice. The effects of HIF-1α on immune adaptation were mediated through VEGFA-dependent activation of the AKT and ERK signaling pathways, which induced an antiapoptotic gene expression network in tumor cells. Conclusions: Our study therefore establishes a link between immune selection, overexpression of HIF-1α, and cancer immune adaptation under normoxia, providing new opportunities for molecular intervention in patients with cancer. Clin Cancer Res; 21(6); 1438–46. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-1979

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Normoxic and hypoxic stabilization of HIF signaling in tumor cells promotes resistance to cytotoxic T lymphocyte-mediated lysis.

    “Normoxic and hypoxic stabilization of HIF signaling in tumor cells promotes resistance to cytotoxic T lymphocyte–mediated lysis”

    From Hypoxic control of metastasis (2016) · cites this paper as [51]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 29 · Cited by 64

Authors
Lee, Y.-H., Bae, H. C., Noh, K. H., Song, K.-H., Ye, S.-K., Mao, C.-P., Lee, K.-M., Wu, T.-C., & Kim, T. W.
Affiliations
  • Korea University (KR)
  • Seoul National University (KR)
  • Johns Hopkins University (US)
Corresponding author
Wu, T.-C.
Venue
Clinical Cancer Research
Published
2015-03-12
Volume
21
Issue
6
Pages
1438-1446
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2144381820
Cited by
64
References
29
Citations by year
2026: 5 · 2025: 5 · 2024: 4 · 2023: 2 · 2022: 10 · 2021: 9 · 2020: 5 · 2019: 7 · 2018: 8 · 2017: 4 · 2016: 3 · 2015: 2
FWCI
1.87
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R01CA114425, CA114425-01, F30CA177221, R01CA183040, P50 CA 96784-06, CA177221, P20CA192988, P50CA096784, R21CA178255, R21CA180953, P50CA098252)
  • National Institute of General Medical Sciences (T32GM007309)
  • National Institute of Allergy and Infectious Diseases (T32AI007247)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
HIF-1α, normoxia, immune selection, tumor immune evasion, cytotoxic T lymphocytes, VEGF-A, Akt signaling, ERK signaling, anti-apoptotic gene expression, tumor evolution, host immune surveillance
MeSH terms
Animals, Female, Humans, Mice, Inbred C57BL, Neoplasms, Oxygen, Signal Transduction, Apoptosis, Tumor Escape, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins c-akt, Mice, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review